Loading the session
Loading the session
Loading instrument
$14.81
−2.57%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:13 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −14.9% (SPY −1.6%, XLV +13.5%). 3 months: −32.9% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AKTS, SPY and XLV · as of 4 Nov 2026
4.3M shares were sold short at the 15 Oct 2026 settlement; covering them would take 11.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $15.20 was 23.7% below its 50-day average ($19.93) and 27.4% below its 200-day average ($20.94). The 50-day average crossed below the 200-day on 27 Oct 2026, 6 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
2 Nov 2026 volume of 898.2K shares was 2.6× the average of the 30 sessions before it (348.3K), as the price fell 8.4%. SPY traded 1.2× its own average that session.
Daily volume against a 30-session baseline · as of 2 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
July 6, 2026
−16.37%June 12, 2026
+12.69%March 27, 2026
−13.79%